Juxing Medical recently issued an announcement stating that it is considering establishing a joint venture with New Genetron Holding Limited (Genetron Health) in Singapore to jointly develop the precision medicine market in Indonesia, Malaysia, and Singapore.
The joint venture plans to set up a new entity in Indonesia, focusing on the design, construction, and operation of clinical molecular diagnostic laboratories, with a key focus on precision oncology, and will establish localized production lines for in vitro diagnostic reagents and kits in due course.
The joint venture will establish clinical collaborations with well-known hospitals and medical institutions in Indonesia for sample collection, product validation, and early clinical applications. Both parties will form a joint board of directors and management team to jointly handle regulatory filings and compliance matters in Indonesia. Future plans include gradual expansion into neighboring Southeast Asian markets.
Juxing Medical currently focuses on distribution of in vitro diagnostic products and medical film production in China, while Genetron Health is a leading precision oncology platform company with multi-omics technology and FDA-approved products.
This collaboration aims to combine Genetron's technological advantages with Juxing Medical's channel experience to accelerate the localized implementation of high-value cancer diagnosis and treatment solutions in Indonesia and Southeast Asia.
Juxing Medical recently issued an announcement stating that it is considering establishing a joint venture with New Genetron Holding Limited (Genetron Health) in Singapore to jointly develop the precision medicine market in Indonesia, Malaysia, and Singapore.
The joint venture plans to set up a new entity in Indonesia, focusing on the design, construction, and operation of clinical molecular diagnostic laboratories, with a key focus on precision oncology, and will establish localized production lines for in vitro diagnostic reagents and kits in due course.
The joint venture will establish clinical collaborations with well-known hospitals and medical institutions in Indonesia for sample collection, product validation, and early clinical applications. Both parties will form a joint board of directors and management team to jointly handle regulatory filings and compliance matters in Indonesia. Future plans include gradual expansion into neighboring Southeast Asian markets.
Juxing Medical currently focuses on distribution of in vitro diagnostic products and medical film production in China, while Genetron Health is a leading precision oncology platform company with multi-omics technology and FDA-approved products.
This collaboration aims to combine Genetron's technological advantages with Juxing Medical's channel experience to accelerate the localized implementation of high-value cancer diagnosis and treatment solutions in Indonesia and Southeast Asia.